{"analyses":[{"ciLowerLimit":"0.671","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.070","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0825","pValueComment":"P Value is 1-sided","paramType":"Hazard Ratio (HR)","paramValue":"0.847","statisticalComment":"Log-rank test stratified by randomization stratification factor (Intermediate risk MDS, High risk MDS, Very high risk MDS, CMML-2) as per IRT","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.55","upperLimit":"24.74","value":"22.31"},{"groupId":"OG001","lowerLimit":"15.38","upperLimit":"23.72","value":"18.83"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"265"}],"units":"Participants"}],"description":"OS is the time from randomization until death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were randomized to sabatolimab plus Azacitidine","id":"OG000","title":"Sabatolimab (MBG453) + Azacitidine"},{"description":"Participants were randomized to placebo plus Azacitidine","id":"OG001","title":"Placebo + Azacitidine"}],"paramType":"MEDIAN","populationDescription":"FAS comprised of all participants to whom study treatment had been assigned by randomization.","reportingStatus":"POSTED","timeFrame":"up to approx. 39 months","title":"Overall Survival (OS) (Primary Efficacy Results)","type":"PRIMARY","unitOfMeasure":"Months"}